Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.71 |
| ▸ | GCGR | P47871 | 10/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555150 | 0.90 | GCGR (0.58) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL6909011 | 0.83 | GSK3B (0.56) | MAPK14GSK3B | |
| SCHEMBL5216102 | 0.83 | MAPK14 (0.61) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL3561082 | 0.78 | MAPT (0.48) | — | |
| SCHEMBL196861 | 0.71 | GCGR (0.67) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL3265916 | 0.70 | MAPK14 (0.53) | MAPK14GSK3B | |
| SCHEMBL3558118 | 0.70 | GCGR (0.55) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL4806075 | 0.70 | MAPK14 (0.46) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL11778219 | 0.69 | MAPK14 (0.53) | MAPK14GSK3B | |
| SCHEMBL10990175 | 0.69 | MAPK14 (0.53) | MAPK14GCGRGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542680-B1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES AS TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC (US) | 2007-03-07 | — | — | EP | claimed |
| US-6967254-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2005-11-22 | — | — | US | claimed |
| US-20040058918-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2004-03-25 | — | — | US | claimed |
| EP-1542680-B1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES AS TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1542680-B1 | 1, 4, 5-SUBSTITUTED 1, 2-DIHYDRO-PYRAZOL-3-ONE AND 3-ALKOXY-1H-PYRAZOLE DERIVATIVES AS TNF-ALPHA AND INTERLEUKIN LOWERING AGENTS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC (US) | 2007-03-07 | — | — | EP | disclosed |
| US-6967254-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-20040058918-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058918-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MAPT, HMGB1 | MAPK14 1197/4885GCGR 684/4885MAPK13 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.